BI Symposium: Erfüllung strenger Berichtspflichten mit flexiblen, hochadaptiven Controllingwerkzeugen – Integration des internen und externen Berichtswesens bei der Biotest AG

Biotest AG Company Presentation EU 0

May 2013

Biotest AG Company Presentation

Disclaimer

• This document contains forward-looking statements on overall economic development as

well as on the business, earnings, financial and asset situation of Biotest AG and its

subsidiaries. These statements are based on current plans, estimates, forecasts and

expectations of the company and thus are subject to risks and elements of uncertainty

that could result in deviation of actual developments from expected developments.

• The forward-looking statements are only valid at the time of publication. Biotest does not

intend to update the forward-looking statements and assumes no obligation to do so.

• All figures reported relate to the Continuing Operations of the Biotest Group. After the sale

of the Medical Diagnostic activities to Bio-Rad Laboratories Inc. and the sale of the

segment Microbiological Monitoring to Merck KGaA, both activities are being reported as

Discontinued Operation

• All comparative figures relate to the corresponding last year´s period, unless stated

otherwise.

• The information contained herein serves information purposes and does not constitute

any offer for sale or subscription of or solicitation or invitation of any offer to buy or

subscribe for any securities. In case of a future offering it should be noted that such

offered securities will solely be offered on the basis of an approved securities prospectus.

Any investment decision should only be made based on the information contained in such

prospectus.

Company Presentation EU 1 Biotest AG

Headquarter in Dreieich/Germany

(Frankfurt area)

Subsidiaries in 11 countries worldwide

Employees (FTE)*: 1,834

Thereof 48% located outside Germany

Founded in 1946, IPO in 1987, SDAX in 2007

(preference shares)

Biotest shares:

6,595,242 ordinary shares

6,595,242 preference shares

*: as of June 30, 2013

Biotest Group

Headquarter, Dreieich


Shareholder structure


Biotest AG

Preference shares: 6.6 mio no voting rights, but higher dividend

Free Float: 100%

Ordinary shares: 6.6 mio with voting rights

OGEL GmbH*: 50.03%

KSK Biberach*: ~24%

Free Float: ~26%

50.0% of total capital,

0% of voting rights

50.0% of total capital,

and 100% of voting rights

* as of June 2013 based on notifications

Biotest: History and milestones achieved


1946: Biotest-

Serum Institut

GmbH

1946 2013

1948:

Test-Serum

Anti-D

1961: New

production

facility at

Dreieich 1968: First

subsidiary

outside

Germany

(Italy)

1971: Market

launch of

Intraglobin®

1991: Start of

Microbiological

Monitoring

1987: IPO

2004: Start of

modernized

Plasma Proteins

production

2007:

- Clinical testing of

monoclonal antibodies

- Acquisition of Nabi

- Preference share in SDAX

2010: Divestment of

Medical Diagnostics

2011:

- Divestment of

Microbiological Monitoring

- Biotest- AbbVie

Deal for BT 061

2012: Bivigam®

Launch in US

From plasma to a medicinal product


§ § §

Plasma

Donation

Frac-

tionation Purification

Filling &

Packaging

Coagulation Factors

Immunoglobulins

Hyperimmunoglobulins

Human Albumin

Safety - Quality

Supervised and regulated by v. Paul-Ehrlich Institut, FDA etc.

Products

• effective

• safe

• natural

Biotest production sites


Production site Dreieich Production site Florida, USA

Biotest produces in Dreieich (near Frankfurt) and in Boca Raton, Florida,USA

1.800 employees worldwide

CapEx per year: approx. € 35 Mio.

Three strategic areas of therapy: Products - Pipeline

7

Haematology Clinical

Immunology Intensive Care

Company Presentation EU Biotest AG

Products

Haemoctin®

Haemonine®

Pipeline

BT-062

Intratect®

Hepatect® , Nabi-HB®

Zutectra®

Cytotect®

Varitect®

Bivigam ®

Fovepta®

Civacir®

Cytotect 70 (BT-094)

Tregalizumab (BT-061)

Pentaglobin®

Humanalbumine

Biseko®

Cofact®

IgM-Concentrate

Fibrinogen

0

100

200

300

400

500

1 2 3 4 5 6 7 8 9

Continue and accelerate growth

8

Biotest Group: Sales 2004-2012 (€ million)*

2004 2005 2006 2007 2008 2009 2010 2011 2012

141.9

339.4

440.0

Sales target

for 2020:

~ € 1 billion

* On a comparable basis, only pharmaceutical activities

Biotest AG Company Presentation EU

Biotest guidance in 2013

422 440

0

100

200

300

400

500

2011 2012 2013e

(EURm)


+10-15%

+4.3%

Sales growth 10 – 15% vs. 2012 EBIT growth 10 – 15% vs. 2012

41,6 44,7

0

20

40

60

2011 2012 2013e

(EURm)

+7.5%

+10-15%

Very strong balance sheet and share performance

10

With the successful capital

increase Biotest is well prepared

for new investments in expanding

our capacity

High equity portion of 61% allows

a high debt capacity

Higher number of shares

outstanding and new investors

should lead to an increased

liquidity in our shares

Biotest AG Company Presentation EU

Share price preference shares

+ 64.8% in one

year

Sources: Handelsblatt.com 12.09.2013

Biotest AG 11

Addresses of group figures – internal and external

• Bank Analysts

• Investors

• Shareholders

• Banks

• Supervisory Board

• Management Board

Company Presentation EU

Biotest AG 12

Challenges in reporting

• Harmonisation of the external and internal

reporting

• One database of all departments

• Different IT-Structure in 16 subsidiaries in 11

countries

• Preparation for increasing M&A transactions in

the future

Company Presentation EU

Time Schedule


Q1 Q3 Q2 Q1 Q4 Q3 Q4 Q2

2013 2012

Requirements Specification

Proof-of-Concept

Detail-IT-Conception

Implementation SalesTool

Implementation Leg. Consolidation

Implementation Mgmt-Tool

Analysis Mgmt-Reporting

Starting GoLive Step-by-Step

Reqiurements Financial Consolidation

Decision Softwaretool Kick-off Project

As-is Analysis Review Process

Software-Selection

User Requirements

Functional Design

Go Live

Zielarchitektur für Controlling und Finance


Oberfläche

(User-Interface) Mobiles

Reporting

Standard-

/Hochglanz-

Reporting Ad-Hoc-Abfragen

„Listen“,

progr. Abfragen

Dashboards,

Cockpits

Basis für eine

erfolgreiche und

nachhaltige

Unternehmens-

steuerung

Gemeinsamen Datenbasis aller Controlling und Finance Daten aus allen Biotest BGs

Controlling Finance/

Konsolidierung

(Unternehmens)Planung

(Sales, Budget, Finance, …)

Operative

Systeme und

Prozesse

der BGs SAP ECC 6.0 SAP R/3 4.7 Non-SAP

Automatische Datenübernahme

XLS-Upload/ Man.Eingabe

FlatFile Upload

Modell Legale Konsolidierung


Anbindung der operativen SAP-Systeme


FI-GL

CO-PA

Dreieich CO-PA

Reporting

Pre-

Consolidation

Cube

BPC- Cube

/CPMB/CONSOLIDATION

CO-PA

Agregations

Cube

SAP

ERP

SAP BW SAP BPC

CO-PA

Reporting

CO-PA

Mapping

Cube CO-PA

BGs

FI-GL

Agregations

Cube

FI

Mapping

Cube

MAPPING ERP to

SAP BPC

FI-Bilanz

Reporting

Manuelle Erfassungslayouts

• Transparente Datenerfassung für Non-SAP Gesellschaften

• Anwendungsfreundliche und bekannte Benutzeroberfläche

• Nachvollziehbare Datenanpassungen

• Flexible Anpassungen bei neuen Strukturen oder neune gesetzlichen Anforderungen


Lessons learned

• Abstimmung und Vereinheitlichung der Abschlussprozesse

• Definition einheitlicher Kennzahlen

• Operative Buchungsvorschriften für Detailauswertungen

• Anwenderfreundlichkeit

• Transparente und revisonssichere Prozesse

• Testvorgehen / Aufsatzpunkt Nachfahren der Altabschlüsse


Haben Sie Fragen?


Contact

Biotest AG:

Dirk Neumüller

Director Group Reporting

Phone: +49 (0) 6103 - 801 -269

E-Mail: [email protected]

21 Biotest AG Company Presentation EU

IBsolution GmbH:

Thomas Eichelbaum

Project Manager

Phone: +49 (0) 7131 - 2711 -1087

E-Mail: [email protected]

Business

BI Symposium: Erfüllung strenger Berichtspflichten mit flexiblen, hochadaptiven Controllingwerkzeugen – Integration des internen und externen Berichtswesens bei der Biotest AG